Infants who receive nirsevimab may have a lower risk for hospitalisation for RSV-related lower respiratory tract infection ...

The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to notify clinicians and caregivers about increases in respiratory syncytial virus (RSV) ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent ...

Nirsevimab, a long-acting monoclonal antibody that confers passive immunity for infants up to 6 months old, was approved in ...

RSV is a highly contagious respiratory virus that can cause serious illness in babies and young children, and can be spread ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from ...

Respiratory syncytial virus (RSV) remains a leading cause of severe lower respiratory infections among infants, particularly ...

ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct, rapid and durable protection through 5 months, a typical RSV season, with the same dose regardless of ...

Six routine vaccines that have safeguarded millions from serious diseases are no longer being recommended for all children by the CDC.

Respiratory syncytial virus (RSV) is a respiratory infection that has similar symptoms as a cold. But it can be serious for expectant parents who are more at risk for complications from the virus. You ...